Neugeborenenscreening auf Sichelzellkrankheit in Deutschland

Die Sichelzellkrankheit (SCD) ist eine angeborene Blutkrankheit, die unerkannt mit einer signifikanten Frühmorbidität und -mortalität verbunden ist. Da die Diagnose schon bei Geburt mit einer hohen Zuverlässigkeit gestellt werden kann, hat der Gemeinsame Bundesausschuss (G-BA) die Erweiterung des Neugeborenenscreenings (NBS) um die SCD beschlossen. Es ist zu erwarten, dass die SCD eine der häufigsten Diagnosen im dann 18 Zielkrankheiten umfassenden deutschen NBS-Programm sein wird.

• Literatur

• 1 Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med 2017; 376: 1561-1573
• 2 Ballas SK, Lieff S, Benjamin LJ. et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol 2010; 85: 6-13
• 3 Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007; 21: 37-47
• 4 Wiesenfeld SL. Sickle-cell trait in human biological and cultural evolution. Development of agriculture causing increased malaria is bound to gene-pool changes causing malaria reduction. Science 1967; 157: 1134-1140
• 5 Piel FB, Patil AP, Howes RE. et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun 2010; 1: 104
• 6 Piel FB, Patil AP, Howes RE. et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013; 381: 142-151
• 7 Piel FB, Tatem AJ, Huang Z. et al. Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000. Lancet Glob Health 2014; 2: e80-e89
• 8 Lobitz S, Klein J, Brose A. et al. Newborn screening by tandem mass spectrometry confirms the high prevalence of sickle cell disease among German newborns. Ann Hematol 2019; 98: 47-53
• 9 Lobitz S, Frommel C, Brose A. et al. Incidence of sickle cell disease in an unselected cohort of neonates born in Berlin, Germany. Eur J Hum Genet 2014; 22: 1051-1053
• 10 Grosse R, Lukacs Z, Cobos PN. et al. The Prevalence of Sickle Cell Disease and Its Implication for Newborn Screening in Germany (Hamburg Metropolitan Area). Pediatr Blood Cancer 2016; 63: 168-170
• 11 Kunz JB, Awad S, Happich M. et al. Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening. Ann Hematol 2016; 95: 397-402
• 12 Pattloch D. Sichelzellkrankheit unter Neugeborenen in Deutschland: Eine Studie an Routinedaten der AOK. Gesundheitswesen 2019; 81: 986-992
• 13 Andermann A, Blancquaert I, Beauchamp S. et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008; 86: 317-319
• 14 Ribeil JA, Hacein-Bey-Abina S, Payen E. et al. Gene Therapy in a Patient with Sickle Cell Disease. N Engl J Med 2017; 376: 848-855
• 15 Osunkwo I, Manwani D, Kanter J. Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. Ther Adv Hematol 2020; 11: 2040620720955000
• 16 Bernaudin F, Dalle JH, Bories D. et al. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. Haematologica 2020; 105: 91-101
• 17 Voskaridou E, Christoulas D, Bilalis A. et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010; 115: 2354-2363
• 18 Ataga KI, Kutlar A, Kanter J. et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med 2017; 376: 429-439
• 19 Streetly A, Sisodia R, Dick M. et al. Evaluation of newborn sickle cell screening programme in England: 2010–2016. Arch Dis Child 2018; 103: 648-653
• 20 Lobitz S, Telfer P, Cela E. et al. Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference. Br J Haematol 2018; 183: 648-660